CDCheryl Ann Dean

Cheryl Ann Dean

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Cheryl Ann Dean has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Inducing Targeted Mild Hyperthermia in Murine Tumor Models through Photothermal Conversion of Near-infrared Light by Intratumoral Gold Nanorods

    by Kate N. Clark, Barry E. Kennedy, Cheryl Dean, Geetha Subramanian, Erin B. Noftall, Caitlin Gormley, Carman A. Giacomantonio

    Mild hyperthermia (42-48 °C) is a well-established therapeutic modality that can induce controlled tumor cell death and stimulate anti-cancer immune responses. However, delivering heat precisely to tumor tissue while sparing surrounding healthy tissue remains a significant challenge. Traditional hyperthermia methods, such as isolated limb perfusion, require complex, invasive procedures and carry substantial risk of local toxicity and patient morbidity. In contrast, photothermal therapy using gold nanoparticles activated by near-infrared (NIR) light has emerged as a promising, less invasive strategy for achieving localized hyperthermia. Gold nanorods (GNRs), in particular, exhibit tunable optical properties and high photothermal conversion efficiency, making them ideal candidates for precise thermal modulation of tumor sites. Although this technique has shown considerable promise, especially for superficial and accessible tumors, reproducible delivery, spatial confinement, and safety remain active areas of refinement. In this protocol, we present our validated and optimized method for achieving localized, mild hyperthermia using intratumoral injection of biocompatible GNRs followed by short-duration, targeted NIR laser exposure. This approach enables rapid, controllable heating within the therapeutic range, promoting immunogenic tumor cell death and stimulating innate immune responses, mechanisms particularly relevant for immunologically "cold" tumors. Real-time temperature monitoring and local delivery ensure reproducibility, safety, and minimal systemic exposure. This streamlined protocol offers a robust and accessible platform for preclinical studies, supporting broader efforts to harness mild hyperthermia in cancer immunotherapy.


  • Open Access

    LncRNA PART1 Promotes Proliferation and Migration, Is Associated with Cancer Stem Cells, and Alters the miRNA Landscape in Triple-Negative Breast Cancer

    by Brianne M. Cruickshank, Marie-Claire D. Wasson, Justin M. Brown, Wasundara Fernando, Jaganathan Venkatesh, Olivia L. Walker, Fiorella Morales-Quintanilla, Margaret L. Dahn, Dejan Vidovic, Cheryl A. Dean, et al.

    Triple-negative breast cancers (TNBCs) are aggressive, lack targeted therapies and are enriched in cancer stem cells (CSCs). Novel therapies which target CSCs within these tumors would likely lead to improved outcomes for TNBC patients. Long non-coding RNAs (lncRNAs) are potential therapeutic targets for TNBC and CSCs. We demonstrate that lncRNA prostate androgen regulated transcript 1 (PART1) is enriched in TNBCs and in Aldefluorhigh CSCs, and is associated with worse outcomes among basal-like breast cancer patients. Although PART1 is androgen inducible in breast cancer cells, analysis of patient tumors indicates its androgen regulation has minimal clinical impact. Knockdown of PART1 in TNBC cell lines and a patient-derived xenograft decreased cell proliferation, migration, tumor growth, and mammosphere formation potential. Transcriptome analyses revealed that the lncRNA affects expression of hundreds of genes (e.g., myosin-Va, MYO5A; zinc fingers and homeoboxes protein 2, ZHX2). MiRNA 4.0 GeneChip and TaqMan assays identified multiple miRNAs that are regulated by cytoplasmic PART1, including miR-190a-3p, miR-937-5p, miR-22-5p, miR-30b-3p, and miR-6870-5p. We confirmed the novel interaction between PART1 and miR-937-5p. In general, miRNAs altered by PART1 were less abundant than PART1, potentially leading to cell line-specific effects in terms miRNA-PART1 interactions and gene regulation. Together, the altered miRNA landscape induced by PART1 explains most of the protein-coding gene regulation changes (e.g., MYO5A) induced by PART1 in TNBC.


  • Open Access

    Human-specific GAPDH RT-qPCR is an accurate and sensitive method of xenograft metastasis quantification

    by Margaret Lois Dahn, Cheryl A Dean, Diana B Jo, Krysta M Coyle, Paola Marcato

    Metastasis is the primary cause of cancer-related mortality. Having experimental models that accurately reflect changes in the metastatic burden is imperative for developing improved treatments and a better understanding of the disease. The murine xenograft tumor model mimics the human scenario and provides a platform for in vivo and ex vivo metastasis quantification analyses. Histological analysis of hematoxylin and eosin (H&E) stained thin sections has been the gold standard for quantifying metastasis ex vivo but gaining favor for its ease and accuracy is reverse transcription-qualitative polymerase chain reaction (RT-qPCR). Herein we directly compare histological and RT-qPCR-based methods for quantifying lung metastasis in a murine xenograft tumor model. Furthermore, we have introduced a variation of the RT-qPCR method; human-specific glyceraldehyde 3-phosphate dehydrogenase (GAPDH) RT-qPCR, which allows quantification of metastasis in xenograft models, without the requirement of overexpression of exogenous genes. Human-specific GAPDH RT-qPCR detected increased lung metastasis resulting from aldehyde dehydrogenase 1A3 (ALDH1A3) expression in MDA-MB-231 breast cancer cells orthotopically implanted in NOD/SCID mice. Further, in the xenograft tumor model, human-specific GAPDH RT-qPCR was more sensitive and cost-effective than quantification of lung metastasis by histological analysis of H&E stained fixed thin sections. The two assays were highly correlative in terms of determining relative metastatic burden, suggesting that the human-specific GAPDH RT-qPCR method could be used as a standard method for quantification of disseminated human cells in murine xenograft models.


  • Open Access

    DNA Methylation Predicts the Response of Triple-Negative Breast Cancers to All-Trans Retinoic Acid

    by Krysta Mila Coyle, Cheryl A. Dean, Margaret Lois Thomas, Dejan Vidovic, Carman A. Giacomantonio, Lucy Helyer, Paola Marcato

    All-trans retinoic acid (atRA) regulates gene expression and is used to treat acute promyelocytic leukemia. Attempts to use atRA in breast cancer without a stratification strategy have resulted in limited overall effectiveness. To identify biomarkers for the treatment of triple-negative breast cancer (TNBC) with atRA, we characterized the effects of atRA on the tumor growth of 13 TNBC cell lines. This resulted in a range of effects that was not predictable based on previously hypothesized predictors of response, such as the levels of atRA nuclear shuttling proteins fatty acid binding protein 5 (FABP5) and cellular retinoic acid binding protein 2 (CRABP2). Transcriptional profiling revealed that atRA induced distinct gene expression changes in the sensitive versus resistant cell lines that were mostly independent of the presence of retinoic acid response elements (RAREs) or peroxisome proliferator response elements (PPREs). Given the importance of DNA methylation in regulating gene expression, we hypothesized that differential DNA methylation could predict the response of TNBCs to atRA. We identified over 1400 sites that were differentially methylated between atRA resistant and sensitive cell lines. These CpG sites predicted the response of four TNBC patient-derived xenografts to atRA, and we utilized these xenografts to refine the profile and identified that as many as 17% of TNBC patients could benefit from atRA treatment. These data illustrate that differential methylation of specific CpGs may be useful biomarkers for predicting the response of patient tumors to atRA treatment.


  • Open Access

    Core Needle Biopsy of Breast Cancer Tumors Increases Distant Metastases in a Mouse Model

    by Edward Gitau Mathenge, Cheryl Ann Dean, Derek Clements, Ahmad Vaghar-Kashani, Steffany Photopoulos, Krysta Mila Coyle, Michael Giacomantonio, Benjamin Malueth, Anna Nunokawa, Julie Jordan, et al.